HomeNYSE:NVO

NYSE:NVO

Novo Nordisk Receives Favorable CHMP Opinion for Insulin Icodec

Novo Nordisk Receives Favorable CHMP Opinion for Insulin Icodec

March 22, 2024

Novo Nordisk’s Strategic Move: Acquiring Hypertension Drug for $1.3 Billion

Novo Nordisk’s Strategic Move: Acquiring Hypertension Drug for $1.3 Billion

October 17, 2023